KR890000666A - 응고활성을 갖는 인자 viii:c-형 분자 - Google Patents

응고활성을 갖는 인자 viii:c-형 분자 Download PDF

Info

Publication number
KR890000666A
KR890000666A KR1019880007295A KR880007295A KR890000666A KR 890000666 A KR890000666 A KR 890000666A KR 1019880007295 A KR1019880007295 A KR 1019880007295A KR 880007295 A KR880007295 A KR 880007295A KR 890000666 A KR890000666 A KR 890000666A
Authority
KR
South Korea
Prior art keywords
factor viii
derivative
arg
medicament
coagulation activity
Prior art date
Application number
KR1019880007295A
Other languages
English (en)
Inventor
랭너 클라우스-디터
아만 에곤
쿠퍼 한스
제틀마이슬 게르트
후버 베르나르트
Original Assignee
필립 스타인, 헤리베르트 버그
베링베르크 아크티엔게셜샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필립 스타인, 헤리베르트 버그, 베링베르크 아크티엔게셜샤프트 filed Critical 필립 스타인, 헤리베르트 버그
Publication of KR890000666A publication Critical patent/KR890000666A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

응고활성을 갖는 인자 VIII:C-형 분자
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 완전한 F VIII:C서열을 구성하는 5개의 클론을 도시한 것이다.
제2도는 플라스미드 pGX3254를 도시한 것이다.
제3a도는 pGX3254의 제한지도이다.
제3b도는 pGX3788의 제한지도이다.
제3c도는 pGX3789의 제한지도이다.

Claims (10)

  1. Arg372에 천연 트롬빈 분해 부위가 보존되고, 새로운 트롬빈 분해 부위가 Agr740에 형성되어 있으며, Arg1648및 Arg1689에 존재하는 트롬빈 분해 부위가 결실된 인자 VIII:C 유도체.
  2. 제1항에 있어서, 천연 분자의 아미노산 741 내지 1689가 결실된 인자 VIII:C 유도체.
  3. 제1항 또는 2항에 정의된 인자 VIII:C 유도체 및 이의 대립 형질체 및 변이체를 암호화하는 DNA 서열.
  4. 제1항 또는 2항에 따른 인자 VIII:C 유도체를 함유하는 약제.
  5. 제4항에 따른 약제를 함유하는 주사 용액.
  6. 응고 장해의 치료용 약제를 제조하기 위한 제1항 또는 2항에 따른 인자 VIII:C 유도체의 용도.
  7. 제3항에 따른 DNA 서열을 포함하는 DNA 구조물 및 벡터.
  8. 제7항에 따른 DNA 구조물 또는 벡터를 함유하는 원핵 또는 진핵 세포.
  9. 제8항에 따른 세포를 발현시킴을 특징으로 하여, 인자 VIII:C 유도체를 제조하는 방법.
  10. 진단 보조제의 제조를 위한 제1항 또는 2항에 따른 인자 VIII:C 유도체의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880007295A 1987-06-19 1988-06-17 응고활성을 갖는 인자 viii:c-형 분자 KR890000666A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873720246 DE3720246A1 (de) 1987-06-19 1987-06-19 Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
DEP3720246.4 1987-06-19

Publications (1)

Publication Number Publication Date
KR890000666A true KR890000666A (ko) 1989-03-16

Family

ID=6329877

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880007295A KR890000666A (ko) 1987-06-19 1988-06-17 응고활성을 갖는 인자 viii:c-형 분자

Country Status (8)

Country Link
EP (1) EP0295597A3 (ko)
JP (1) JPS6425799A (ko)
KR (1) KR890000666A (ko)
AU (1) AU609829B2 (ko)
DE (1) DE3720246A1 (ko)
DK (1) DK332888A (ko)
FI (1) FI882890A (ko)
PT (1) PT87752B (ko)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
WO1997003194A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
CA2776503C (en) 2009-10-02 2020-07-28 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
EP4382170A2 (en) 2009-12-06 2024-06-12 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
AR087091A1 (es) 2011-07-08 2014-02-12 Biogen Idec Hemophilia Inc Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
LT2804623T (lt) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
LT2882450T (lt) 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
RS61387B1 (sr) 2013-02-15 2021-02-26 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
UY35462A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.
EP3013358A4 (en) 2013-06-28 2017-03-22 Biogen MA Inc. Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CN116731201A (zh) 2014-01-10 2023-09-12 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
AU2017214378B2 (en) 2016-02-01 2023-05-04 Bioverativ Therapeutics Inc. Optimized Factor VIII genes
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
MA46968A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
EP3665289A1 (en) 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
UY38160A (es) 2018-04-04 2019-11-29 Sigilon Therapeutics Inc Partículas implantables y métodos relacionados
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
MX2021015897A (es) 2019-06-19 2022-04-18 Bioverativ Therapeutics Inc Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
NO872932L (no) * 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
AU606925B2 (en) * 1987-01-30 1991-02-21 Biogen, Inc. A method for producing factor viii in high yield
EP0690126B1 (en) * 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI882890A (fi) 1988-12-20
PT87752A (pt) 1988-07-01
EP0295597A3 (de) 1990-05-02
FI882890A0 (fi) 1988-06-16
EP0295597A2 (de) 1988-12-21
DE3720246A1 (de) 1988-12-29
DK332888A (da) 1988-12-20
AU1810388A (en) 1988-12-22
JPS6425799A (en) 1989-01-27
PT87752B (pt) 1992-10-30
AU609829B2 (en) 1991-05-09
DK332888D0 (da) 1988-06-17

Similar Documents

Publication Publication Date Title
KR890000666A (ko) 응고활성을 갖는 인자 viii:c-형 분자
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
ES2636653T3 (es) Mutantes degradantes del proteoglucano para el tratamiento del SNC
KR840004781A (ko) 인체의 조직 플라스미노겐 활성화제
KR900002795A (ko) 하이브리드 단백질c 작제물 및 그들의 제조방법
KR880007734A (ko) 폴리펩타이드 유도체
NO176921C (no) Genteknologisk fremgangsmåte for fremstilling av et tPA-lignende protein, samt vertscelle som er i stand til å uttrykke et slikt protein
ATE5001T1 (de) Verfahren zur herstellung eines ausgewaehlten proteins.
BR9608019A (pt) Uma nova proteína e um processo para a preparação da mesma'
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
DE68914316T2 (de) Polypeptide aus Vipergift und deren Genexpression.
DE3682891D1 (de) Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen.
US5859223A (en) Soluble CR1 derivatives
KR930010177A (ko) 하이브리드 형질전환 성장인자
Barrow et al. Kidney antihemophilic factor. Partial purification and some properties
KR870004139A (ko) 인체 λ-인터페론의 생물학적 활성 유도체를 제조하는 방법
DE68918279D1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
JPS6420095A (en) Polypeptide having anti-blood coagulating action
LeBoeuf et al. Human apolipoprotein B: partial amino acid sequence
KR910003095A (ko) 사람의 단백질 c변이체 및 이의 제조방법
KR880009127A (ko) 용성 성숙 hIL-β 및 변경된 생물학적 활성을 갖는 유도체를 이 콜라이에서 고도로 발현시키는 플라즈미드 및 그 방법
DE3780199T2 (de) Modifiziertes enzym.
KR850700008A (ko) 의약용과 미용에 사용되는 조성물의 제조방법
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
Koteliansky et al. Filamin, a high relative molecular mass actin‐binding protein from smooth muscles, promotes actin polymerization

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid